

FILE 'HOME' ENTERED AT 16:34:30 ON 21 APR 2005

=> file bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'ADISCTI' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:34:50 ON 21 APR 2005

FILE 'ANABSTR' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:34:50 ON 21 APR 2005

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 16:34:50 ON 21 APR 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:34:50 ON 21 APR 2005

FILE 'CAPLUS' ENTERED AT 16:34:50 ON 21 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (c) 2005 DECHEMA eV

FILE 'CEN' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:34:50 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:34:50 ON 21 APR 2005

FILE 'FOMAD' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:34:50 ON 21 APR 2005

FILE 'HEALSAFE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:34:50 ON 21 APR 2005

FILE 'NIOSHTIC' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:34:50 ON 21 APR 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 16:34:50 ON 21 APR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:34:50 ON 21 APR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHARMAML' ENTERED AT 16:34:50 ON 21 APR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:34:50 ON 21 APR 2005

COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHIN' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PROMT' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:34:50 ON 21 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 16:34:50 ON 21 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:34:50 ON 21 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 16:34:50 ON 21 APR 2005
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	90.92	91.13

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 16:35:02 ON 21 APR 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view

search error messages that display as 0* with SET DETAIL OFF.

=> mst-1 (w) _inhibitor and administering

4 FILES SEARCHED...

24 FILES SEARCHED...

2 FILE DGENE

34 FILES SEARCHED...

55 FILES SEARCHED...

69 FILES SEARCHED...

1 FILE WPIDS

1 FILE WPINDEX

3 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L1 QUE MST-1 (W) _INHIBITOR AND ADMINISTERING

=> d rank

F1 2 DGENE

F2 1 WPIDS

F3 1 WPINDEX

=> file dgene wpids wpindex

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.67

98.80

FILE 'DGENE' ENTERED AT 16:42:29 ON 21 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 16:42:29 ON 21 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> mst-1 (w) _inhibitor and administering

L2 3 MST-1 (W) _INHIBITOR AND ADMINISTERING

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.15

103.95

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 16:43:02 ON 21 APR 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> mst-1 (w) inhibitor and administering

23 FILES SEARCHED...

2 FILE DGENE

34 FILES SEARCHED...

40 FILES SEARCHED...

67 FILES SEARCHED...

1 FILE WPIDS

73 FILES SEARCHED...

0* FILE WPINDEX

2 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L3 QUE MST-1 (W) INHIBITOR AND ADMINISTERING

=> file dgene wpids wpindex

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.16

118.11

FILE 'DGENE' ENTERED AT 16:57:15 ON 21 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 16:57:15 ON 21 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' TEMPORARILY UNAVAILABLE

If this message appears repeatedly, please notify the Help Desk.

Enter "HELP STN" for information on contacting the nearest STN Help

Desk by telephone or via SEND in the STNMAIL file.

=> mst-1 (w) inhibitor and administering

L4 3 MST-1 (W) INHIBITOR AND ADMINISTERING

=> d ab bib 1-4

L4 ANSWER 1 OF 3 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AB The invention describes a method of treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis in a mammal comprises **administering** a compound or agent that blocks or otherwise inhibits mammalian sterile 20-like kinase-1(Mst1) or the Mst1 pathway. Also described are: a method for reducing cardiomyopathy in a mammal by administration of a **Mst-1 inhibitor**; a method for reducing the risk of cardiomyopathy or cardiac dysfunction in a mammal; a method of cardioprotection by **administering** an inhibitor of Mst1 is administered in conjunction with or following therapy with a compound or drug which is cardiotoxic; a method of screening for compounds which modulate cardiac myocyte apoptosis; a composition for modulating cardiac myocyte apoptosis comprising an Mst1 inhibitor; a pharmaceutical composition for treating or ameliorating cardiac disease in a mammal comprising one or more Mst1 inhibitor or a combination of one or more Mst1 inhibitor and one or more other compounds for treating cardiac disease or atherosclerosis, and a carrier; an assay system for screening of potential compounds or agents to modulate Mst1 activity of target mammalian cells by interrupting or potentiating the Mst1 or Mst1 pathway where the test compound or agent is administered to a cellular sample to determine its effect upon the kinase activity, cleavage status or phosphorylation status of Mst1, by comparison with a control; an assay system for screening compounds or agents for the ability to modulate the activity of Mst1; and an animal model of cardiac disease including cardiac myopathy comprising a transgenic animal where Mst1 expression or activity is enhanced. The method is useful for treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis, such diseases include congestive heart failure, cardiomyopathy, including ischemic and non-ischemic cardiomyopathy, coronary artery disease, arrhythmias, fibrosis of the heart, valve defects, atherosclerosis, and instances where facilitation of enhanced heart function or maintenance of cardiac myocytes is desired. The method is effective against cardiac disorders, may be used to protect against the side effects of cardiotoxic drugs and gives effective combination therapy when used with prior art cardiac drugs. This is the amino acid sequence of a human sterile 20-like kinase-1 (Mst-1) epitope used to raise an anti-Mst-1-antibody.

AN ADT08273 peptide DGENE
 TI Treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis in a mammal comprises **administering** a compound or agent that blocks or otherwise inhibits mammalian sterile 20-like kinase-1(Mst1) or the Mst1 pathway.
 IN Vatner S F; Sadoshima J
 PA (VATN-I) VATNER S F.
 (SADO-I) SADOSHIMA J.
 PI US 2004213794 A1 20041028 63
 AI US 2003-683576 20031010
 PRAI US 2002-418002P 20021011
 DT Patent
 LA English
 OS 2004-765576 [75]
 DESC Mammalian sterile 20-like kinase-1 (Mst1) epitope seqid 4.

L4 ANSWER 2 OF 3 DGENE COPYRIGHT 2005 The Thomson Corp on STN
 AB The invention describes a method of treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis in a mammal comprises **administering** a compound or agent that blocks or otherwise inhibits mammalian sterile 20-like kinase-1(Mst1) or the Mst1 pathway. Also described are: a method for reducing cardiomyopathy in a mammal by administration of a **Mst-1 inhibitor**; a method for reducing the risk of cardiomyopathy or cardiac dysfunction in a mammal; a method of cardioprotection by **administering** an inhibitor of Mst1 is administered in conjunction with or following therapy with a compound or drug which is cardiotoxic; a method of screening for compounds which modulate cardiac myocyte apoptosis; a composition for modulating cardiac myocyte apoptosis comprising an Mst1 inhibitor; a pharmaceutical composition for treating or ameliorating cardiac disease in a mammal comprising one or more Mst1 inhibitor or a combination of one or more Mst1 inhibitor and one or more other compounds for treating cardiac disease or atherosclerosis, and a carrier; an assay system for screening of potential compounds or agents to modulate Mst1 activity of target mammalian cells by interrupting or potentiating the Mst1 or Mst1 pathway where the test compound or agent is administered to a cellular sample to determine its effect upon the kinase activity, cleavage status or phosphorylation status of Mst1, by comparison with a control; an assay system for screening compounds or agents for the ability to modulate the activity of Mst1; and an animal model of cardiac disease including cardiac myopathy comprising a transgenic animal where Mst1 expression or activity is enhanced. The method is useful for treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis, such diseases include congestive heart failure, cardiomyopathy, including ischemic and non-ischemic cardiomyopathy, coronary artery disease, arrhythmias, fibrosis of the heart, valve defects, atherosclerosis, and instances where facilitation of enhanced heart function or maintenance of cardiac myocytes is desired. The method is effective against cardiac disorders, may be used to protect against the side effects of cardiotoxic drugs and gives effective combination therapy when used with prior art cardiac drugs. This sequence represents a polynucleotide associated with the method of the invention. Note: This sequence appears in the sequence listing but is not further described in the specification.

AN ADT08272 DNA DGENE
 TI Treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis in a mammal comprises **administering** a compound or agent that blocks or otherwise inhibits mammalian sterile 20-like kinase-1(Mst1) or the Mst1 pathway.
 IN Vatner S F; Sadoshima J
 PA (VATN-I) VATNER S F.
 (SADO-I) SADOSHIMA J.
 PI US 2004213794 A1 20041028 63

AI US 2003-683576 20031010
PRAI US 2002-418002P 20021011
DT Patent
LA English
OS 2004-765576 [75]
DESC Cardiac disease treatment associated human DNA seqid 2.

L4 ANSWER 3 OF 3 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AB US2004213794 A UPAB: 20041122

NOVELTY - Treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis in a mammal comprises **administering** a compound or agent that blocks or otherwise inhibits mammalian sterile 20-like kinase-1(Mst1) or the Mst1 pathway.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for reducing cardiomyopathy in a mammal by administration of a **Mst-1 inhibitor**;

(2) a method for reducing the risk of cardiomyopathy or cardiac dysfunction in a mammal where the mammal has suffered a myocardial infarct or other coronary event where blood flow to the heart is reduced by **administering** an Mst1 inhibitor or Mst1 pathway inhibitor;

(3) a method of cardioprotection by **administering** an inhibitor of Mst1 is administered in conjunction with or following therapy with a compound or drug which is cardiotoxic;

(4) a method of screening for compounds which modulate cardiac myocyte apoptosis;

(5) a composition for modulating cardiac myocyte apoptosis comprising an Mst1 inhibitor;

(6) a pharmaceutical composition for treating or ameliorating cardiac disease in a mammal comprising one or more Mst1 inhibitor or a combination of one or more Mst1 inhibitor and one or more other compounds for treating cardiac disease or atherosclerosis, and a carrier;

(7) an assay system for screening of potential compounds or agents to modulate Mst1 activity of target mammalian cells by interrupting or potentiating the Mst1 or Mst1 pathway where the test compound or agent is administered to a cellular sample to determine its effect upon the kinase activity, cleavage status or phosphorylation status of Mst1, by comparison with a control;

(8) an assay system for screening compounds or agents for the ability to modulate the activity of Mst1; and

(9) an animal model of cardiac disease including cardiac myopathy comprising a transgenic animal where Mst1 expression or activity is enhanced.

ACTIVITY - Cardiovascular-Gen.; Cardiant; Vasotropic; Antiarrhythmic; Antiinflammatory; Antiarteriosclerotic.

No biological data given.

MECHANISM OF ACTION - Mst-Inhibitor-1.

USE - The method is useful for treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis, such diseases include congestive heart failure, cardiomyopathy, including ischemic and non-ischemic cardiomyopathy, coronary artery disease, arrhythmias, fibrosis of the heart, valve defects, atherosclerosis, and instances where facilitation of enhanced heart function or maintenance of cardiac myocytes is desired.

ADVANTAGE - The method is effective against cardiac disorders, may be used to protect against the side effects of cardiotoxic drugs and gives effective combination therapy when used with prior art cardiac drugs.

Dwg.0/23

AN 2004-765576 [75] WPIDS

DNC C2004-268360

TI Treating or ameliorating cardiac disease or modulating cardiac myocyte apoptosis in a mammal comprises **administering** a compound or agent that blocks or otherwise inhibits mammalian sterile 20-like

kinase-1(Mst1) or the Mst1 pathway.

DC B04 B05 D16

IN SADOSHIMA, J; VATNER, S F

PA (SADO-I) SADOSHIMA J; (VATN-I) VATNER S F

CYC 1

PI US 2004213794 A1 20041028 (200475)* 63

ADT US 2004213794 A1 Provisional US 2002-418002P 20021011, US 2003-683576
20031010

PRAI US 2002-418002P 20021011; US 2003-683576 20031010

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.72	158.83

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 17:02:26 ON 21 APR 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> mst1.(w) inhibitor and administering

1 FILE BIOTECHABS

1 FILE BIOTECHDS

1 FILE CAPLUS

19 FILES SEARCHED...

2 FILE DGENE

1 FILE IFIPAT

53 FILES SEARCHED...

2 FILE USPATFULL